OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2004-01-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if OSI-774 will improve overall survival of
patients with incurable stage IIIB/IV non-small cell lung cancer compared to standard of
care. OSI-774 is a new type of drug under evaluation called an epidermal growth factor
receptor (EGFR). OSI-774 is an investigational drug that has not yet been approved by the
U.S. Food and Drug Administration (FDA).
Phase:
Phase 3
Details
Lead Sponsor:
OSI Pharmaceuticals
Collaborators:
Canadian Cancer Trials Group NCIC Clinical Trials Group